SCHEMBL21451006

SCHEMBL21451006

O=c1c2cc(F)ccc2sc2c(-n3cccc3)nc3ccccc3c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.45
TOP2A P11388 1/20 0.45
CYP19A1 P11511 1/20 0.39
GLA P06280 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MPI P34949 2/20 0.36
PMM2 O15305 1/20 0.36
PHOSPHO1 Q8TCT1 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
TLR9 Q9NR96 1/20 0.36
AKR1B1 P15121 3/20 0.36
KMT2A Q03164 2/20 0.35
NPC1 O15118 2/20 0.35
TDO2 P48775 2/20 0.35
RAB9A P51151 2/20 0.35
IDO2 Q6ZQW0 2/20 0.35
MEN1 O00255 1/20 0.35
APAF1 O14727 1/20 0.35
MITF O75030 1/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21451012 0.88 TOP1 (0.42) TOP1TOP2ACYP19A1GLAL3MBTL1
SCHEMBL21450992 0.86 TOP1 (0.43) TOP1TOP2ACYP19A1GLAL3MBTL1
SCHEMBL21450998 0.84 TOP1 (0.56) TOP1TOP2AGLAL3MBTL1KMT2A
SCHEMBL21450999 0.84 TOP1 (0.55) TOP1TOP2AGLAL3MBTL1KMT2A
SCHEMBL21450906 0.83 TOP1 (0.43) TOP1TOP2AGLAL3MBTL1MPI
SCHEMBL21451019 0.82 TOP1 (0.69) TOP1TOP2AHRH4
SCHEMBL21451020 0.82 HRH4 (0.56) TOP1TOP2AHRH4
SCHEMBL30089858 0.82 TOP1 (0.69) TOP1TOP2AHRH4
SCHEMBL21451011 0.82 TOP1 (0.53) TOP1TOP2AGLAKMT2ANPC1
SCHEMBL30089834 0.82 HRH4 (0.56) TOP1TOP2AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885CYP19A1 3408/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885CYP19A1 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.